Contract award

Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Bicycle Therapeutics (“Bicycle”) that it expects to be completed over the next six months.  The project involves modelling and the use of bioinformatics data in support of target identification for undisclosed Bicycle programs.


Physiomics CEO, Dr Jim Millen, commented: “We are delighted that, having worked on a number of clinical stage projects with Bicycle, we are now complementing these with a substantial project focused on earlier stage drug development.  We look forward to working once again with Bicycle’s talented team.”






Physiomics plc                                                  

Dr Jim Millen, CEO

+44 (0)1865 784 980


Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341


Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494



Notes to Editor


About Physiomics


Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys.  Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.  Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 projects, over 40 targets and 70 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.